Novo Nordisk on Biden's price criticism: A complex problem abused for political purposes

Both Novo Nordisk and rival Eli Lilly were the targets of an op-ed written by US President Joe Biden and Senator Bernie Sanders.

by MARKETWIRE ‎

Novo Nordisk is disappointed by Tuesday’s harsh criticism from President Joe Biden and Senator Bernie Sanders of the company’s pricing of its super-selling weight loss drugs Wegovy and Ozempic for type 2 diabetes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles

Receive our daily newsletters

Access our app

Get full access for you and your coworkers

Start a free company trial today

Joe Biden demands lower prices for Wegovy and Ozempic
For subscribers
Novo Nordisk CEO to testify before senate committee in September
For subscribers
Cosmetic Ozempic use under fire in EU amid drug shortages

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Daugaard Jens Henrik/Ritzau Scanpix

Other

Brain signaling pathway discovered could lead to new migraine treatments

”The next step for us will be to identify the proteins with the most potential for drug development,” says the study’s lead author.

For subscribers

Foto: Gonzalo Fuentes/Reuters/Ritzau Scanpix

Pharma & biotech

French state investment firm eyes stake in Sanofi consumer unit

Pharma & biotech

Companies hold back on cutting China ties despite Biosecure Act

Pharma & biotech

Leo Pharma's HR director leaves after less than a year – interim replacement found

For subscribers

”I don’t think this is a strong enough signal to take the medication away from patients," says one neuro-opthamologist who wrote an accompanying paper for the study. | Foto: Hollie Adams/Reuters/Ritzau Scanpix

Pharma & biotech

Study links Novo Nordisk blockbuster to rare vision loss

Pharma & biotech

Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss

For subscribers

Analyst calls for calm after study links Novo Nordisk's bestsellers to sight loss

”It’s a small study and it’s not the first time smaller studies have signaled side effects,” he points out.

For subscribers

Foto: Cole Burston/Reuters/Ritzau Scanpix

Sanofi gets Dupixent approved for the treatment of COPD in the EU

In the US, Sanofi expects a response by September 27.

Lars Nørby Johansen has influenced several of the largest companies in Denmark, such as Falck and Dong, and today, in addition to the William Demant Foundation, he is also chairman of the board of Copenhagen Airport and Montana Furniture. | Foto: Lars Krabbe

William Demant Foundation chairman distances himself from fired executive- but will still put him on boards

Chairman of the Board Lars Nørby Johansen defends the fact that the William Demant Foundation continues to vote a VP fired from Demant onto the boards of other companies that the foundation owns.

For subscribers

Major investor on ALK: Pipeline is lacking

ALK needs to find new sources of revenue if it is to maintain growth of more than 10%, according to the major investor.

For subscribers

Studies have found that the new drug slows down the progression of Alzheimer's. | Foto: Mike Blake/Reuters/Ritzau Scanpix

Eli Lilly gets Alzheimer's drug approved in the US

Kisunla is a treatment for the early symptoms of the degenerative disease.

Novo Nordisk bombards US TV viewers with Wegovy commercials

The total cost of Novo Nordisk’s commercial slot for Wegovy amounted to USD 42m in June.

For subscribers

Novo Nordisk implements hiring freeze in certain departments

Since 2021, Novo Nordisk has increased its number of employees by 20,000 to total 66,000.

For subscribers

Pharma & biotech

Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss

The study is not designed to show a causal relationship with the eye condition, the pharmaceutical company points out.

For subscribers

Pharma & biotech

Novo Nordisk: Patients are more important than the climate

The pharmaceutical giant’s greenhouse gas emissions grew 53% last year. According to the company’s head of sustainability, the increase is due to ongoing production expansions.

For subscribers